Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mecompy-Plus is a multi-ingredient nutritional supplement and finished generic formulation manufactured by Kaizen Pharmaceuticals. It is a combination product containing methylcobalamin (1500 mcg), alpha-lipoic acid (100 mg), pyridoxine hydrochloride (3 mg), folic acid (1.5 mg), and several minerals and nutrients including zinc, chromium, selenium, biotin, and inositol. The formulation is primarily indicated for the treatment of Vitamin B12 deficiency, including pernicious anemia, and for managing symptoms of peripheral neuropathy such as pain, numbness, and paralysis. Methylcobalamin serves as a neuroprotective cofactor for methionine synthase, which is essential for myelin synthesis, while alpha-lipoic acid provides antioxidant support to mitigate oxidative stress in nerve tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mecompy-Plus.